• Publications
  • Influence
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
TLDR
N-BNP-guided treatment of heart failure reduced total cardiovascular events, delayed time to first event compared with intensive clinically guided treatment, and changed left-ventricular function, quality of life, renal function, and adverse events were similar in both groups. Expand
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.
TLDR
Plasma N-BNP measured 2 to 4 days after myocardial infarction independently predicted left ventricular function and 2-year survival and Stratification of patients into low- and high-risk groups can be facilitated by plasma natriuretic peptide or BNP measurements, and one of these could reasonably be included in the routine clinical workup of patients after my cardiac infarctions. Expand
Plasma brain natriuretic peptide in assessment of acute dyspnoea
TLDR
The finding that plasma BNP is raised in Dyspnoeic patients with HF but not in acutely breathless patients with PLD, suggests that rapid BNP assays may assist in the diagnosis of patients with acute dyspnoea. Expand
Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment
TLDR
The relationship between immunoreactive (IR) NT‐proBNP and BNP‐32 in normal and hypertensive subjects and in patients with cardiac impairment, as well as the regional plasma concentrations in patients undergoing routine cardiac catheterization are investigated. Expand
Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.
TLDR
High MPO is a risk factor for long-term mortality and adds prognostic value to LVEF and plasma NT-proBNP measurements and protein carbonyl levels are elevated in plasma after acute MI, apparently via independent mechanisms. Expand
Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath.
TLDR
Measurement of BNP or N-BNP is useful in the diagnosis of HF in acute dyspnea and Commercially available assays compare favorably with well-validated laboratory assays. Expand
Growth differentiation factor 15, ST2, high‐sensitivity troponin T, and N‐terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction
TLDR
Growth differentiation factor 15, ST2, high‐sensitivity troponin T, and N‐terminal pro brain natriuretic peptide are biomarkers of distinct mechanisms that may contribute to the pathophysiology of heart failure. Expand
2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial.
TLDR
Using the ADP, a large group of patients was successfully identified as at low short-term risk of a MACE and therefore suitable for rapid discharge from the emergency department with early follow-up, which could decrease the observation period required for some patients with chest pain. Expand
Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome.
TLDR
An early-discharge strategy using an hs-TnI assay and TIMI score ≤ 1 had similar safety as previously reported, with the potential to decrease the observation periods and admissions for approximately 40% of patients with suspected ACS. Expand
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death)
TLDR
Compared with clinically guided treatment and UC, hormone-guided treatment selectively improves longer-term mortality in patients <or=75 years of age. Expand
...
1
2
3
4
5
...